NIH clinical study establishes human model of influenza pathogenesis

A National Institutes of Health (NIH) clinical study of healthy adult volunteers who consented to be infected with the 2009 H1N1 influenza virus under carefully controlled conditions has provided researchers with concrete information about the minimum dose of virus needed to produce mild-to-moderate illness. The study also gives a clearer picture of how much time elapses between a known time of infection, the start of viral shedding (a signal of contagiousness), the development of an immune response, and the onset and duration of influenza symptoms. The data obtained from this study provide a basis for more rapid, cost-effective clinical trials to evaluate new influenza drugs or to determine the efficacy of candidate vaccines for both seasonal and pandemic influenza.

In the study, 46 volunteers were divided into five groups and exposed to in escalating doses. The virus, synthesized in the lab under Good Manufacturing Practice conditions, was genetically identical to the virus that caused 2009 H1N1 . The volunteers all gave informed consent and subsequently were admitted to an isolation unit at the NIH Clinical Center in Bethesda, Md., for a minimum of eight days following virus exposure. The volunteers' health was closely monitored throughout their stay in the clinic and for two months afterward. The researchers sought to determine the minimum dose of virus needed to produce both shedding of live virus in and mild or moderate in 60 percent or more of dosed volunteers. When the scientists administered an influenza virus dose of 107 TCID50 (a measure of the amount of virus required to produce cell death in 50 percent of inoculated with virus) to 13 volunteers, 9 (or 69 percent) shed virus and developed symptoms. Lower dosages did not generate responses that met this threshold, thereby establishing the minimum dose of influenza virus needed to produce mild-to-moderate illness.

Researchers from NIH's National Institute of Allergy and Infectious Diseases (NIAID) presented the preliminary study results at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Denver.

More information: www.abstractsonline.com/Plan/V… A5DF-1D00766558B8%7d

add to favorites email to friend print save as pdf

Related Stories

Ferrets, pigs susceptible to H7N9 avian influenza virus

May 23, 2013

Chinese and U.S. scientists have used virus isolated from a person who died from H7N9 avian influenza infection to determine whether the virus could infect and be transmitted between ferrets. Ferrets are often used as a mammalian ...

Recommended for you

Ebola outbreak nears end in Nigeria

11 minutes ago

The Ebola outbreak in Nigeria is almost over, after an ordeal that began in July when a sick man with US-Liberian citizenship flew there from Liberia, US health authorities said Tuesday.

Diuretics in proton pump inhibitor-associated hypomagnesemia

1 hour ago

Proton pump inhibitor (PPI) therapy is associated with hospitalization for hypomagnesemia, particularly among patients also receiving diuretics, according to research published this week in PLOS Medicine. The study, conduc ...

Families wait in agony for word on Ebola patients

7 hours ago

First the ring tone echoed outside the barbed-wire-topped walls of the Ebola clinic. Then came the wails of grief, as news spread that 31-year-old Rose Johnson was dead just days after she was brought here ...

China to open first high security bio laboratory

7 hours ago

China's first high-security biosafety laboratory will be ready for use by December, in a move hailed as a "crucial" moment in the fight against pathogens such as the Ebola virus, officials said Tuesday.

User comments